RecruitingNot applicableNCT06122077

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

The PROACT LUNG study is a prospective multi-center observational study to validate a blood-based test for the early detection of lung cancer by collecting blood samples from high-risk participants who will undergo a routine, standard-of-care screening Low-Dose Computed Tomography (LDCT).

Checked against the public recordLast updated Aug 5, 2025 · Source: ClinicalTrials.gov

StatusRecruiting
PhaseNot applicable
U.S. locations36
SponsorFreenome Holdings Inc.
01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Freenome Holdings Inc.
Interventions being studied
Diagnostic Test: blood draw
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

Inclusion Criteria: 1. Age 50 years or older within 30 days of enrollment 2. Current or former smokers with a cumulative smoking history of ≥ 20 pack-year 3. Able to comprehend and willing to sign and date the informed consent and HIPAA authorization documents Exclusion Criteria: 1. Any active therapy for cancer, including but not limited to surgery, chemotherapy, biologic therapy, immunotherapy, and/or radiation therapy at the time of enrollment 2. History of any malignancy within prior 5 years of enrollment (except for non- melanoma skin cancer) 3. History of organ, tissue, and bone marrow transplantation 4. Screened for lung cancer or having chest CT scan 12 months before enrollment 5. Having signs and symptoms of lung cancer such as hemoptysis, superior vena cava syndrome, Cushing syndrome, and Pancoast syndrome 6. Received a blood transfusion in the 30 days preceding enrollment 7. Known to be pregnant 8. Participated or currently participating in another Freenome-sponsored clinical study 9. Participated or currently participating in a clinical research study in which an experimental medication has been administered during the 60 days preceding enrollment 10. Any condition that in the opinion of the Investigator should not be enrolled in the study

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Science 37Los Angeles, California
  • Stamford HospitalStamford, Connecticut
  • Hillcrest Medical ResearchDeLand, Florida
  • Universal Axon Clinical ResearchDoral, Florida
  • I.H.S Health, LLCKissimmee, Florida
  • United Medical ResearchPort Orange, Florida
  • Charter ResearchThe Villages, Florida
  • Charter ResearchWinter Park, Florida
  • SpeciCare, IncGainesville, Georgia
  • University of ChicagoChicago, Illinois
  • WalgreensDeerfield, Illinois
  • Springfield Clinic, LLPSpringfield, Illinois

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 5, 2025. Always confirm current availability with the study team.

View original record ↗